Company intelligence / Profile preview
China Oncology Focus
Road Town, British Virgin Islands
- Ownership
- Private
- Development stage
- Other
01
Overview
Socazolimab (anti-PD-L1 monoclonal antibody) received regulatory approval in China for recurrent cervical cancer (December 2023). Gimatecan (Top I inhibitor) is in Phase 2 for primary peritoneal carcinoma. Zotiraciclib (multi-kinase inhibitor: CDK2/5/7/9/FLT3/JAK2) is in Phase 1 for high grade glioma. Glufosfamide (alkylating agent) has advanced to a pivotal Phase 3 trial for second-line pancreatic cancer elsewhere. The company focuses on developing in-house combinations, with an aim for NDA submissions in China.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodySmall moleculeOncolytic virus therapyAntibody-drug conjugate
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Sorrento Therapeutics (PD-L1 antibody asset)Auransa (license for AU018 program)Shenogen Pharma (collaboration on oncology programs)
Beyond the preview
Go deeper on China Oncology Focus.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on China Oncology Focus.